The Journal of Steroid Biochemistry and Molecular Biology
Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report☆
Introduction
Estrogens are considered to play important roles in the development and progression of hormone-dependent human breast cancer. Human breast cancers express increased aromatase enzyme and activity compared with normal breast tissue. The overexpression of aromatase appears to play an important role in estrogen related development and progression of some human breast cancers [1], [2], [3], [4]. Aromatase inhibitor therapy is one of the endocrine treatments available to breast cancer patients. It has therefore become very important to predict which patients will respond prior to initiation of therapy.
At present, aromatase inhibitors appear to exert their effects primarily through the reduction of aromatase activity in non-ovarian tissue in postmenopausal women. Some studies have demonstrated a positive correlation between intratumoral aromatase activity and response to treatment with various aromatase inhibitors [3], [4]. If in situ estrogen biosynthesis and local concentrations are important in the cancer cases that respond to aromatase inhibitor treatment, the tumors must also express the aromatase enzyme as well as estrogen and progesterone receptors. Accordingly, measurement of aromatase activity might serve as a useful tool for prediction of responses to aromatase inhibitors. Test of this concept has been limited by the need to determine aromatase by biochemical methods in fresh tissue. What is needed is a precise, sensitive, and quantifiable method for detecting aromatase in archival materials or formalin-fixed and paraffin-embedded tissue. No anti-aromatase antibodies have been specifically designed for this purpose.
Existing antibodies directed against aromatase are available. However, they are in ever dwindling supplies and the results from studies using them have been controversial in terms of tumor aromatase localization [5], [6], [7], [8], [9]. Therefore, this study was undertaken as an international collaboration in order to develop aromatase antibodies that can be used to assess aromatase expression in fixed breast cancer tissue and test whether these measurements are predictive of responsiveness to aromatase inhibitors. This manuscript represents an interim progress report of this project.
Section snippets
Materials
Tissues were fixed in 3.7% formalin and embedded in paraffin. Control tissues included normal placenta and cycling ovary. All human breast carcinoma (10 cases) used for initial screening were invasive ductal carcinoma and retrieved from surgical pathology files of Department of Pathology, Tohoku University Hospital.
Production of monoclonal antibodies (MAbs) against aromatase
Preparation of aromatase antigen, its fixation prior to injection, initial screening for antibody production, and development of hybridomas were carried out in a fashion similar to
Selection criteria for MAbs to aromatase and results of hybridoma screening
The strategy for screening hybridomas was to assay the initial fusion wells by ELISA against purified GST–aromatase used as antigen and with free GST. Only positives for GST–aromatase and negatives for the GST moiety of the antigen were selected. ELISA positives were further screened by Western blot against purified GST–aromatase, GST–aromatase in crude extracts of Sf9 cells and free GST. Hybridoma products that gave a specific reaction for GST–aromatase by Western blot with little or no
Discussion
Due to marked improvements in immunostaining methods and the antibodies used, it is now possible to immunolocalize the increasing number of antigens in routinely processed specimens (i.e. 10% formalin-fixed and paraffin-embedded tissue). Immunohistochemistry can now be performed rapidly and without many technical difficulties. We reasoned that antibodies against aromatase and an immunohistochemical staining system would allow semiquantitation of aromatase immunoreactivity in tissue sections in
Acknowledgements
The authors acknowledge the technical assistance of Kurt Christensen and Lori Sherman (UCHSC).
References (15)
- et al.
The importance of local synthesis of estrogen with the breast
Steroids
(1987) - et al.
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders
Hum. Pathol.
(1994) - et al.
Comparison of different antibodies for detection of progesterone receptor in breast cancer
Steroids
(2002) - et al.
Preparation and characterization of polyclonal and monoclonal antibodies against human aromatase cytochrome P-450 (P450 AROM) and their use in its purification
Arch. Biochem. Biophys.
(1985) - et al.
Oestradiol synthesis from C19 steroids by human breast cancer
Br. J. Cancer
(1974) - et al.
Significance of aromatase activity in human breast cancer
Cancer Res.
(1982) - et al.
Correlation of breast tumor aromatase activity and response to aromatase inhibition with aminoglutethimide
Oncology
(1987)
Cited by (41)
Prostaglandin E<inf>2</inf> down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity– breast cancer connection
2019, Journal of Biological ChemistryCitation Excerpt :Primers for aromatase, SIRT1720, and an antibody to β-actin were purchased from Sigma. Monoclonal aromatase antibody 677 was obtained from the Baylor College of Medicine (39). Antibodies to SIRT1 (1:1000; D1D7), p300 (1:1000; D8Z4E), ATF3 (1:1000; D2Y5W), and HIF-1α (1:1000; D2U3T) and microsomal isolation kits were bought from Cell Signaling Technology.
Hsp90 and PKM2 drive the expression of aromatase in Li-Fraumeni syndrome breast adipose stromal cells
2016, Journal of Biological ChemistryIntracrine oestrogen production and action in breast cancer: An epigenetic focus
2013, Journal of Steroid Biochemistry and Molecular BiologyAromatase, breast cancer and obesity: A complex interaction
2012, Trends in Endocrinology and MetabolismCitation Excerpt :Immunoreactive aromatase has been localized to both malignant epithelial cells and surrounding fibroblasts in breast tumor tissues [61–63]. The biologic relevance of immunoreactive aromatase detected by different antibodies, however, remained debatable [64]. Markedly high levels of aromatase enzyme activity and gene expression via activation of the promoter I.3/II have been consistently detected in breast adipose tissue or fibroblasts, freshly isolated from breast tissue, with or without cancer [24,60,65].
Tissue physiology and pathology of aromatase
2012, SteroidsGrowth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms
2011, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :Aromatase is one of the key enzymes for the biosynthesis of estrogen. The enzyme expression is highly elevated in human breast cancer tissue than in normal breast tissue, as measured by enzyme activity assay and reverse transcription-polymerase chain reaction (RT-PCR) analysis [2,4–8]. High expression of aromatase in breast cancer cells and surrounding adipose stromal cells contributes significantly to breast tumor development and growth in the patients [2,6].
- ☆
Presented at the VI International Aromatase Conference: AROMATASE 2002, Kyoto, Japan, 26–30 October 2002.